Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 1/20 | 0.80 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.77 |
| ▸ | SIGMAR1 | Q99720 | 5/20 | 0.69 |
| ▸ | MEN1 | O00255 | 2/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.62 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.61 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.60 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.60 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.60 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.60 |
| ▸ | NCOR2 | Q9Y618 | 2/20 | 0.60 |
| ▸ | MPO | P05164 | 1/20 | 0.54 |
| ▸ | GAA | P10253 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | ACHE | P22303 | 2/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7982481 | 1.00 | MAOA (0.80) | MAOACHRM2SIGMAR1MEN1KMT2A | |
| SCHEMBL8911797 | 1.00 | MAOA (0.80) | MAOACHRM2SIGMAR1MEN1KMT2A | |
| SCHEMBL7986745 | 0.98 | CHRM2 (0.81) | MAOACHRM2SIGMAR1MEN1KMT2A | |
| SCHEMBL8030792 | 0.98 | CHRM2 (0.81) | MAOACHRM2SIGMAR1MEN1KMT2A | |
| SCHEMBL8034858 | 0.98 | CHRM2 (0.81) | MAOACHRM2SIGMAR1MEN1KMT2A | |
| SCHEMBL1040171 | 0.98 | MAOA (0.76) | MAOACHRM2SIGMAR1MEN1KMT2A | |
| SCHEMBL8029033 | 0.96 | CHRM2 (0.78) | MAOACHRM2SIGMAR1MEN1KMT2A | |
| SCHEMBL8032640 | 0.96 | CHRM2 (0.78) | MAOACHRM2SIGMAR1MEN1KMT2A | |
| SCHEMBL8034873 | 0.94 | CHRM2 (0.81) | MAOACHRM2SIGMAR1MEN1KMT2A | |
| SCHEMBL8029046 | 0.92 | CHRM2 (0.77) | MAOACHRM2SIGMAR1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103890088-B | Resin composition | AJINOMOTO CO.,INC. (JP) | 2016-05-18 | — | — | CN | claimed |
| CN-111378181-A | Force-induced responsive polymer with single-hybrid network structure | 翁秋梅 | 2020-07-07 | — | — | CN | disclosed |
| US-20140234364-A1 | TOTAL SYNTHESIS AND IMMUNOLOGICAL EVALUATION OF SACCHARIDE MOIETIES OF THE LIPOPOLYSACCHARIDE FROM NEISSERIA MENINGITIDIS | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2014-08-21 | — | — | US | disclosed |
| CN-103890088-A | Resin composition | AJINOMOTO KK | 2014-06-25 | — | — | CN | disclosed |
| WO-2013041732-A1 | TOTAL SYNTHESIS AND IMMUNOLOGICAL EVALUATION OF SACCHARIDE MOIETIES OF THE LIPOPOLYSACCHARIDE FROM NEISSERIA MENINGITIDIS | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2013-03-28 | — | — | WO | disclosed |
| EP-2573100-A1 | Total synthesis of the core tetrasaccharide of the lipopolysaccharide from Neisseria meningitidis | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2013-03-27 | — | — | EP | disclosed |
| US-6214833-B1 | MADE BY ACYLATION | ZAMBON GROUP S.P.A. (IT) | 2001-04-10 | — | — | US | disclosed |
| EP-0970075-A1 | PYRIMIDINONE-1,3-OXATHIOLANE DERIVATIVES WITH ANTIVIRAL ACTIVITY | ZAMBON GROUP S.p.A. (IT) | 2000-01-12 | — | — | EP | disclosed |
| WO-1998043972-A1 | PYRIMIDINONE-1,3-OXATHIOLANE DERIVATIVES WITH ANTIVIRAL ACTIVITY | ZAMBON GROUP S.P.A. (IT) | 1998-10-08 | — | — | WO | disclosed |
| WO-1997048705-A1 | POTASSIUM CHANNEL BLOCKERS | UNIVERSITY COLLEGE LONDON (GB) | 1997-12-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140234364-A1 | TOTAL SYNTHESIS AND IMMUNOLOGICAL EVALUATION OF SACCHARIDE MOIETIES OF THE LIPOPOLYSACCHARIDE FROM NEISSERIA MENINGITIDIS | FUT5, DAD1, STT3B | MAOA 2347/4885CHRM2 3598/4885SIGMAR1 1857/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.